partners since 2016
duration of the program
About the Pediatric Praziquantel Consortium
Praziquantel (PZQ), the gold standard treatment for schistosomiasis, is currently available in large oral tablets that are suitable only for adults and school-aged children. Due to the size of the tablet, its bitter taste, and a lack of clinical data, an appropriate treatment for very young children does not exist. The consortium addresses this issue, and has developed a new orally disintegrating PZQ formulation that is currently in clinical development. The consortium is supported by grants from the Bill and Melinda Gates Foundation in 2013 and the Global Health Initiative Technology Fund in 2014 and 2015. Visit the Pediatric Praziquantel Consortium website for more information about the program.
Bridging industry interests and societal needs
TI Pharma – now part of Lygature – helped to set up the consortium and fulfils an independent ‘broker’ role, a key ingredient of successful public-private development partnerships. Reflecting the consortium’s position at the crossroad between industry and society, the contributions being made by Lygature from January 2016 include:
- Coordination and governance. As consortium coordinator, Lygature provides necessary governance in terms of monitoring progress, finance, IP management, and collaborations. In addition, it successfully takes the lead in fundraising to support the clinical trial program (current total value: EUR 5m).
- Communication and dissemination . Lygature pro-actively coordinates the engagement with key stakeholders to share the consortium’s ambition to make a meaningful contribution to tropical medicine and health innovation in endemic countries. Responsibilities include (but are not limited to): presenting at (inter)national conferences; writing of (scientific) articles and news items; and development of the consortium’s communication strategy, website, and visual identity.
The Pediatric Praziquantel Consortium is an example of the Lygature mission to bring together public and private partners, and so to make a meaningful contribution to tropical medicine. The project relies heavily on Lygature’s expertise in both management and science. In addition, Lygature has helped to ensure that each partner’s needs, interests, and objectives are met.
Lygature together with
A new formulation to fight Schistosomiasis
The GHIT Fund, one of the funders for the Pediatric Praziquantel Consortium, created a 4 minute video explaining the Consortium’s work and its current challenges.
Watch the video here.
The Pediatric Praziquantel Consortium featured in 1st JAGntd newsletter
The Pediatric Praziquantel Consortium was featured in the first issue of the Japan Alliance on Global Neglected Tropical Diseases (JAGntd) newsletter. The newsletter introduces public health challenges for preschool-aged children with schistosomiasis and the Consortium’s efforts in addressing those.
Taking the next step towards access with continued support from the GHIT Fund
The GHIT Fund provided the Consortium with positive feedback following the grant interview and the Consortium looks back on many years of good collaboration with the Fund. The Consortium is grateful for GHIT’s continued support in finding a solution for schistosomiasis in preschool aged children, and will continue its work to ensure future affordability, availability and adoption of this new medicine.
Despite schistosomiasis being one of the most prevalent parasitic diseases worldwide, preschool aged children are currently left untreated in public health programs due to lack of a suitable pediatric formulation. With the help of the GHIT Fund, the Consortium aims to meet this medical need. With this fourth grant the GHIT Fund reaffirms its confidence in the Consortium’s work.
Read the Consortium’s full press release here.
Read the GHIT Fund press release here.